What Are the Roles of Proprotein Convertases in the Immune Escape of Tumors?

Furin 3 PCSK9 4 PCs 2 TME 6 cancer 10 cytokines 7 immunoediting 9 proprotein convertases 1 tumor hallmarks 8 tumor immune escape 5

Journal

Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304

Informations de publication

Date de publication:
19 Dec 2022
Historique:
received: 27 10 2022
revised: 28 11 2022
accepted: 12 12 2022
entrez: 23 12 2022
pubmed: 24 12 2022
medline: 24 12 2022
Statut: epublish

Résumé

Protein convertases (PCs) play a significant role in post-translational procedures by transforming inactive precursor proteins into their active forms. The role of PCs is crucial for cellular homeostasis because they are involved in cell signaling. They have also been described in many diseases such as Alzheimer's and cancer. Cancer cells are secretory cells that send signals to the tumor microenvironment (TME), remodeling the surrounding space for their own benefits. One of the most important components of the TME is the immune system of the tumor. In this review, we describe recent discoveries that link PCs to the immune escape of tumors. Among PCs, many findings have determined the role of Furin (PC3) as a paramount enzyme causing the TME to induce tumor immune evasion. The overexpression of various cytokines and proteins, for instance, IL10 and TGF-B, moves the TME towards the presence of Tregs and, consequently, immune tolerance. Furthermore, Furin is implicated in the regulation of macrophage activity that contributes to the increased impairment of DCs (dendritic cells) and T effector cells. Moreover, Furin interferes in the MHC Class_1 proteolytic cleavage in the trans-Golgi network. In tumors, the T cytotoxic lymphocytes (CTLs) response is impeded by the PD1 receptor (PD1-R) located on CTLs and its ligand, PDL1, located on cancer cells. The inhibition of Furin is a subtle means of enhancing the antitumor response by repressing PD-1 expression in tumors or macrophage cells. The impacts of other PCs in tumor immune escape have not yet been clarified to the extent that Furin has. Accordingly, the influence of other types of PCs in tumor immune escape is a promising topic for further consideration.

Identifiants

pubmed: 36552048
pii: biomedicines10123292
doi: 10.3390/biomedicines10123292
pmc: PMC9776400
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Références

Immunity. 2018 May 15;48(5):1046-1059.e6
pubmed: 29752063
Medicina (Kaunas). 2019 Dec 30;56(1):
pubmed: 31906017
Oncotarget. 2017 Jun 27;8(26):42214-42225
pubmed: 28178682
Front Immunol. 2021 Apr 29;12:667850
pubmed: 33995401
Nature. 2008 Sep 11;455(7210):246-50
pubmed: 18701887
Cell. 2017 Feb 9;168(4):707-723
pubmed: 28187290
Clin Cancer Res. 2007 Nov 1;13(21):6247-51
pubmed: 17975134
Annu Rev Immunol. 2012;30:531-64
pubmed: 22224781
Nat Immunol. 2002 Nov;3(11):999-1005
pubmed: 12407407
Front Oncol. 2019 Oct 01;9:969
pubmed: 31681561
Nat Rev Drug Discov. 2013 Dec;12(12):931-47
pubmed: 24287781
J Biol Chem. 2009 Oct 16;284(42):28856-64
pubmed: 19635789
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Cancers (Basel). 2018 Jun 11;10(6):
pubmed: 29891791
Cell Mol Life Sci. 2009 Jul;66(13):2075-91
pubmed: 19300906
Nat Immunol. 2002 Nov;3(11):991-8
pubmed: 12407406
Cancer Cell. 2009 Aug 4;16(2):91-102
pubmed: 19647220
Curr Opin Immunol. 1999 Dec;11(6):670-6
pubmed: 10631553
Front Immunol. 2018 Sep 25;9:2159
pubmed: 30319622
Annu Rev Immunol. 2020 Apr 26;38:541-566
pubmed: 32017635
Cancer. 2010 May 1;116(9):2224-33
pubmed: 20209608
Cancer Cell. 2008 Jan;13(1):23-35
pubmed: 18167337
Cancer Lett. 2020 Mar 31;473:50-61
pubmed: 31899298
Crit Rev Immunol. 1992;12(1-2):17-46
pubmed: 1418604
Cytokine Growth Factor Rev. 2007 Feb-Apr;18(1-2):171-82
pubmed: 17329145
Cell. 2017 Sep 7;170(6):1096-1108.e13
pubmed: 28886380
Cell. 1996 Aug 9;86(3):353-64
pubmed: 8756718
J Clin Invest. 2006 Nov;116(11):2995-3005
pubmed: 17080197
Front Immunol. 2017 Mar 17;8:292
pubmed: 28367149
Nat Rev Clin Oncol. 2017 Jul;14(7):399-416
pubmed: 28117416
Nat Rev Cancer. 2019 Oct;19(10):568-586
pubmed: 31462760
N Engl J Med. 2011 Dec 29;365(26):2507-18
pubmed: 22204726
BMC Med. 2015 Mar 05;13:45
pubmed: 25857315
J Biol Chem. 2004 Nov 19;279(47):48865-75
pubmed: 15358785
Kidney Int. 2014 Jul;86(1):175-83
pubmed: 24429406
Immunity. 2019 Dec 17;51(6):1028-1042.e4
pubmed: 31810883
Nat Med. 2013 Oct;19(10):1264-72
pubmed: 24056773
Life Sci. 2020 Oct 1;258:118110
pubmed: 32698074
Oncotarget. 2016 Aug 23;7(34):54392-54404
pubmed: 27527873
Sci Transl Med. 2014 Mar 5;6(226):226ra32
pubmed: 24598590
Cell. 2016 Aug 11;166(4):977-990
pubmed: 27499023
Nat Med. 2018 May;24(5):541-550
pubmed: 29686425
Cell Metab. 2020 Jan 7;31(1):18-25
pubmed: 31607562
Nat Immunol. 2016 May 19;17(6):618-25
pubmed: 27196520
Nat Rev Immunol. 2016 Apr;16(4):220-33
pubmed: 27026074
FASEB J. 2006 Oct;20(12):1954-63
pubmed: 17012247
Science. 1999 Jul 30;285(5428):727-9
pubmed: 10426993
Semin Cancer Biol. 2022 Jan;78:63-77
pubmed: 33711414
J Biol Chem. 2013 Jul 26;288(30):21473-81
pubmed: 23775089
Immunity. 2018 Apr 17;48(4):812-830.e14
pubmed: 29628290
Cancer Cell. 2013 Nov 11;24(5):589-602
pubmed: 24209604
Cancer Cell. 2019 Aug 12;36(2):139-155.e10
pubmed: 31327655
J Cell Physiol. 2003 Jun;195(3):346-55
pubmed: 12704644
Nature. 2008 Jul 24;454(7203):436-44
pubmed: 18650914
Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11515-20
pubmed: 11562487
Nat Rev Cancer. 2004 Jan;4(1):11-22
pubmed: 14708024
Nat Rev Mol Cell Biol. 2002 Oct;3(10):753-66
pubmed: 12360192
Immunol Today. 1997 Feb;18(2):89-95
pubmed: 9057360
Anal Chim Acta. 2015 Jan 1;853:95-115
pubmed: 25467452
Int J Clin Lab Res. 1997;27(2):95-102
pubmed: 9266279
Immunity. 2019 Apr 16;50(4):924-940
pubmed: 30995507
BioDrugs. 2005;19(6):347-54
pubmed: 16392887
J Immunother Cancer. 2019 Dec 4;7(1):339
pubmed: 31801611
Nature. 2011 Jun 08;475(7355):222-5
pubmed: 21654748
J Biol Chem. 2009 Feb 27;284(9):5709-16
pubmed: 19117830
Brain Res. 1999 Nov 27;848(1-2):45-62
pubmed: 10701998
Trends Immunol. 2010 Jun;31(6):220-7
pubmed: 20538542
Mol Carcinog. 2005 Nov;44(3):151-61
pubmed: 16167351
Adv Cancer Res. 2019;144:193-261
pubmed: 31349899
Biochem Pharmacol. 2017 Sep 15;140:8-15
pubmed: 28456517
Cancer Gene Ther. 2022 Jan;29(1):22-36
pubmed: 33402730
Proc Natl Acad Sci U S A. 2005 Feb 8;102(6):2069-74
pubmed: 15677715
Traffic. 2000 Aug;1(8):641-51
pubmed: 11208152
J Immunol. 2018 Aug 1;201(3):825-826
pubmed: 30038034
Int J Hematol. 2011 Mar;93(3):294-300
pubmed: 21374075
J Biol Chem. 2007 Jun 22;282(25):18602-18612
pubmed: 17452316
Cancers (Basel). 2021 Feb 01;13(3):
pubmed: 33535484
Annu Rev Immunol. 2004;22:329-60
pubmed: 15032581
J Exp Med. 2002 Jan 21;195(2):161-9
pubmed: 11805143
J Clin Invest. 2007 May;117(5):1137-46
pubmed: 17476343
Ann N Y Acad Sci. 2013 May;1284:1-5
pubmed: 23651186
Cancer Discov. 2022 Jan;12(1):31-46
pubmed: 35022204
J Am Soc Nephrol. 2010 Apr;21(4):713-22
pubmed: 20110382
Nat Commun. 2018 Jan 16;9(1):249
pubmed: 29339767
J Immunol. 2009 Oct 1;183(7):4639-47
pubmed: 19752221
Nat Rev Cancer. 2008 Aug;8(8):618-31
pubmed: 18633355
EMBO J. 2012 Apr 4;31(7):1630-43
pubmed: 22367392
Front Oncol. 2013 Jul 26;3:197
pubmed: 23898464
Trends Cancer. 2019 Dec;5(12):822-834
pubmed: 31813459
Curr Opin Immunol. 2008 Dec;20(6):663-8
pubmed: 18834938
Nature. 2020 Dec;588(7839):693-698
pubmed: 33177715
Nat Rev Immunol. 2018 Mar;18(3):153-167
pubmed: 28990585
N Engl J Med. 2016 Sep 1;375(9):819-29
pubmed: 27433843
Front Immunol. 2014 Jul 29;5:360
pubmed: 25120546
N Engl J Med. 2000 Aug 3;343(5):338-44
pubmed: 10922424
Cancer Res. 2019 Oct 1;79(19):5008-5021
pubmed: 31358531
Front Immunol. 2021 Mar 09;12:636568
pubmed: 33767702

Auteurs

Elham Mehranzadeh (E)

Cell Biology and Histology Department, Faculty of Medicine and Nursery, University of the Basque Country (UPV/EHU), Barrio Sarriena, sn., 48940 Leioa, Spain.

Olatz Crende (O)

Cell Biology and Histology Department, Faculty of Medicine and Nursery, University of the Basque Country (UPV/EHU), Barrio Sarriena, sn., 48940 Leioa, Spain.

Iker Badiola (I)

Cell Biology and Histology Department, Faculty of Medicine and Nursery, University of the Basque Country (UPV/EHU), Barrio Sarriena, sn., 48940 Leioa, Spain.
Nanokide Therapeutics SL, Ed. ZITEK, Barrio Sarriena, sn., 48940 Leioa, Spain.

Patricia Garcia-Gallastegi (P)

Physiology Department, Faculty of Medicine and Nursery, University of the Basque Country (UPV/EHU), Barrio Sarriena, sn., 48940 Leioa, Spain.

Classifications MeSH